Proposed M&A's, Conference Schedules, Health Awareness Programs, Prestigious Recognitions and FDA Designations - Research Report on Health Management, Acadia, Health Net, NuVasive and Portola Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 29, 2013 NEW YORK, November 29, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Health Management Associates Inc. (NYSE: HMA), ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD), Health Net, Inc. (NYSE: HNT), NuVasive, Inc. (NASDAQ: NUVA) and Portola Pharmaceuticals, Inc. (NASDAQ: PTLA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Health Management Associates Inc. Research Report On November 22, 2013, Health Management Associates Inc. (HMA) and Community Health Systems, Inc. (CHS) announced that the Registration Statement on Form S-4 in relation with its proposed merger has been declared effective by the Securities and Exchange Commission (SEC). "We are pleased that the SEC has completed its review, and we can continue to move towards the successful completion of our acquisition of HMA," said Wayne T. Smith, Chairman, President and CEO of CHS. Under the terms of the transaction, CHS will acquire each issued and outstanding share of the common stock of HMA for $10.50 in cash, c.0.07 of a share of CHS common stock, and a Contingent Value Right, which could yield additional cash consideration of up to $1.00 per share, depending on the outcome of certain litigation matters. The companies expect the transaction to be completed during Q1 2014. The Full Research Report on Health Management Associates Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s=DDD http://www.analystscorner.com/r/full_research_report/9ce8_HMA -- ACADIA Pharmaceuticals, Inc. Research Report On November 26, 2013, Acadia Pharmaceuticals Inc. (Acadia Pharmaceuticals) announced that it will present at the following investor conferences: the Piper Jaffray 25th Annual Healthcare Conference on December 3, 2013, Tuesday at 10:00 a.m. ET; and at the Oppenheimer 24th Annual Healthcare Conference on December 10, 2013, Tuesday at 8:35 a.m. ET. The Company informed that the live webcasts of these presentations will be accessible on its website under the investors section, and an archived recording will be available on the website for two weeks following the applicable presentation. The Full Research Report on ACADIA Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/3eb7_ACAD -- Health Net, Inc. Research Report On November 20, 2013, Health Net, Inc. (Health Net) announced that it is working on raising awareness on the prevalence of diabetes among Americans aged 65 and older, in recognition of American Diabetes Month (which began on November 1, 2013). Health Net stated that its Community Solutions Centers, which provide free health care services and health and wellness resources to all community members and their families all year long, will hold free educational sessions open to the public, which will focus on diabetes prevention and management. "This is a particularly vulnerable group because diabetes can lead to chronic conditions - such as heart disease and kidney disease - that can be fatal," says Patricia Buss, M.D., Medical and Health Care Services Operations Officer for Health Net. According to Centers for Disease Control and Prevention (CDC), the other complications of diabetes can include stroke, hypertension, blindness, nervous system disease and amputations. The Full Research Report on Health Net, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/6995_HNT -- NuVasive, Inc. Research Report On November 26, 2013, NuVasive, Inc. (NuVasive) announced that it been named as one of the fastest growing companies on Deloitte's Technology Fast 500 list, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. "I am very proud that NuVasive has been recognized by Deloitte as one of the fastest growing technology companies in North America," said Chairman and CEO Alex Lukianov. "The achievement is a direct result of our culture of outstanding A-player standards, game-changing products and procedures, and most importantly, a company-wide mission to deliver better outcomes to spine patients around the globe." Lukianov credits the Company's market share taking strategy, driven by Speed of Innovation® and Absolute Responsiveness® with NuVasive's industry leading growth. The Full Research Report on NuVasive, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/c66c_NUVA -- Portola Pharmaceuticals, Inc. Research Report On November 25, 2013, Portola Pharmaceuticals, Inc. (Portola) announced that it has been granted breakthrough therapy designation for andexanet alfa, its investigational Factor Xa inhibitor antidote, by the US FDA. "The FDA's decision to designate andexanet alfa as a breakthrough therapy reaffirms the urgent need for an antidote to Factor Xa inhibitors, and we believe it demonstrates that andexanet alfa's properties and data distinguish it from currently used agents or others in development," said William Lis, Portola's CEO. "Pro-coagulant agents being used in the absence of an antidote are unproven, have limited biological rationale for their effectiveness to reverse Factor Xa inhibitors, and have been shown to cause serious blood clots. Therefore, andexanet alfa marks an important advance in the field, and our goal is to bring it to market as quickly as possible." The Full Research Report on Portola Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/102f_PTLA ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Proposed M&A's, Conference Schedules, Health Awareness Programs, Prestigious Recognitions and FDA Designations - Research Report
Press spacebar to pause and continue. Press esc to stop.